Korean J Gastroenterol.  2020 Dec;76(6):314-321. 10.4166/kjg.2020.115.

Changes in the Crohn’s Disease Activity Index and Safety of Administering Saccharomyces Boulardii in Patients with Crohn’s Disease in Clinical Remission: A Single Hospital-based Retrospective Cohort Study

Affiliations
  • 1Department of Internal Medicine, Kosin University College of Medicine, Busan, Korea

Abstract

Background/Aims
Crohn’s disease (CD) is characterized by uncontrolled inflammation of the intestine. Saccharomyces Boulardii (S. boulardii), a probiotic, stabilizes the intestinal wall. This study examined the changes in the CD activity index (CDAI) after taking S. boulardii in patients with CD in clinical remission.
Methods
In this single hospital-based retrospective cohort study, the medical records of CD patients in clinical remission, who had received S. boulardii for more than 6 months, were reviewed. The CDAI, BMI, and serum levels of hemoglobin (Hb), ferritin, iron, vitamin B12, folate, total protein, albumin, total cholesterol, CRP, and fecal calprotectin (FC) between the initiation and the 6th month were compared. The timing and reasons for the discontinuation were also investigated.
Results
One hundred and fifty-four patients were included, and 92 patients, who received for more than 6 months, were analyzed. The changes in CDAI, BMI, Hb, and total cholesterol were significant as follows: CDAI from 38.52 to 30.53 (p<0.01), BMI (kg/m2 ) from 23.38 to 23.97 (p<0.01), Hb (g/dL) from 13.73 to 14.03 (p<0.01), and total cholesterol (mg/dL) from 154.9 to 161.5 (p<0.01). On the other hand, the changes in FC, CRP, ferritin, vitamin B12, folate, total protein, and albumin were not statistically significant. Only one patient stopped due to a flare-up, but this was not believed to be related to the drug.
Conclusions
In patients with CD in remission, S. boulardii appears to improve the CDAI, BMI, serum Hb, and total cholesterol level without safety issues. Further randomized controlled studies will be needed.

Keyword

Inflammatory bowel diseases; Crohn disease; Probiotics; Saccharomyces boulardii

Figure

  • Fig. 1 Selection of the study participants. CD, Crohn’s disease; S. boulardii, Saccharomyces boulardii.

  • Fig. 2 Kaplan-Meyer survival curve of S. boulardii (n=119). Saccharomyces boulardii, S. boulardii.


Reference

1. Fuller R. 1991; Probiotics in human medicine. Gut. 32:439–442. DOI: 10.1136/gut.32.4.439. PMID: 1902810. PMCID: PMC1379087.
Article
2. Elmer GW, McFarland LV. 2001; Biotherapeutic agents in the treatment of infectious diarrhea. Gastroenterol Clin North Am. 30:837–854. DOI: 10.1016/S0889-8553(05)70213-2.
Article
3. Boirivant M, Strober W. 2007; The mechanism of action of probiotics. Curr Opin Gastroenterol. 23:679–692. DOI: 10.1097/MOG.0b013e3282f0cffc. PMID: 17906447.
Article
4. McFarland LV. 2010; Systematic review and meta-analysis of Saccharomyces boulardii in adult patients. World J Gastroenterol. 16:2202–2222. DOI: 10.3748/wjg.v16.i18.2202. PMID: 20458757. PMCID: PMC2868213.
5. Castagliuolo I, LaMont JT, Nikulasson ST, Pothoulakis C. 1996; Saccharomyces boulardii protease inhibits Clostridium difficile toxin A effects in the rat ileum. Infect Immun. 64:5225–5232. DOI: 10.1128/IAI.64.12.5225-5232.1996. PMID: 8945570. PMCID: PMC174512.
Article
6. Buts JP, Dekeyser N, Stilmant C, Delem E, Smets F, Sokal E. 2006; Saccharomyces boulardii produces in rat small intestine a novel protein phosphatase that inhibits Escherichia coli endotoxin by dephosphorylation. Pediatr Res. 60:24–29. DOI: 10.1203/01.pdr.0000220322.31940.29. PMID: 16690953.
Article
7. Fidan I, Kalkanci A, Yesilyurt E, et al. 2009; Effects of Saccharomyces boulardii on cytokine secretion from intraepithelial lymphocytes infected by Escherichia coli and Candida albicans. Mycoses. 52:29–34. DOI: 10.1111/j.1439-0507.2008.01545.x. PMID: 18627477.
8. Torres J, Bonovas S, Doherty G, et al. 2020; ECCO Guidelines on therapeutics in Crohn's disease: medical treatment. J Crohns Colitis. 14:4–22. DOI: 10.1093/ecco-jcc/jjz180. PMID: 31711158.
9. Garcia Vilela E, De Lourdes De Abreu Ferrari M, Oswaldo Da Gama Torres H, et al. 2008; Influence of Saccharomyces boulardii on the intestinal permeability of patients with Crohn's disease in remission. Scand J Gastroenterol. 43:842–848. DOI: 10.1080/00365520801943354. PMID: 18584523.
10. Guslandi M, Mezzi G, Sorghi M, Testoni PA. 2000; Saccharomyces boulardii in maintenance treatment of Crohn's disease. Dig Dis Sci. 45:1462–1464. DOI: 10.1023/A:1005588911207. PMID: 10961730.
11. Bourreille A, Cadiot G, Le Dreau G, et al. 2013; Saccharomyces boulardii does not prevent relapse of Crohn's disease. Clin Gastroenterol Hepatol. 11:982–987. DOI: 10.1016/j.cgh.2013.02.021. PMID: 23466709.
Article
12. Lichtenstein L, Avni-Biron I, Ben-Bassat O. 2016; Probiotics and prebiotics in Crohn's disease therapies. Best Pract Res Clin Gastroenterol. 30:81–88. DOI: 10.1016/j.bpg.2016.02.002. PMID: 27048899.
Article
13. Plein K, Hotz J. 1993; Therapeutic effects of Saccharomyces boulardii on mild residual symptoms in a stable phase of Crohn's disease with special respect to chronic diarrhea--a pilot study. Z Gastroenterol. 31:129–134.
14. Hanauer SB, Feagan BG, Lichtenstein GR, et al. 2002; Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 359:1541–1549. DOI: 10.1016/S0140-6736(02)08512-4.
Article
15. O'Sullivan M, O'Morain C. 2006; Nutrition in inflammatory bowel disease. Best Pract Res Clin Gastroenterol. 20:561–573. DOI: 10.1016/j.bpg.2006.03.001. PMID: 16782529.
16. Gasche C, Waldhoer T, Feichtenschlager T, et al. 2001; Prediction of response to iron sucrose in inflammatory bowel disease-associated anemia. Am J Gastroenterol. 96:2382–2387. DOI: 10.1111/j.1572-0241.2001.04094.x. PMID: 11513178.
Article
17. Capristo E, Mingrone G, Addolorato G, Greco AV, Gasbarrini G. 1998; Metabolic features of inflammatory bowel disease in a remission phase of the disease activity. J Intern Med. 243:339–347. DOI: 10.1046/j.1365-2796.1998.00254.x. PMID: 9651555.
Article
18. Maaser C, Sturm A, Vavricka SR, et al. 2019; ECCO-ESGAR guideline for diagnostic assessment in IBD part 1: initial diagnosis, monitoring of known IBD, detection of complications. J Crohns Colitis. 13:144–164. DOI: 10.1093/ecco-jcc/jjy113. PMID: 30137275.
Article
19. D'Haens G, Ferrante M, Vermeire S, et al. 2012; Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis. 18:2218–2224. DOI: 10.1002/ibd.22917. PMID: 22344983.
20. Boyle RJ, Robins-Browne RM, Tang ML. 2006; Probiotic use in clinical practice: what are the risks? Am J Clin Nutr. 83:1256–1447. DOI: 10.1093/ajcn/83.6.1256. PMID: 16762934.
Article
21. Klein SM, Elmer GW, McFarland LV, Surawicz CM, Levy RH. 1993; Recovery and elimination of the biotherapeutic agent, Saccharomyces boulardii, in healthy human volunteers. Pharm Res. 10:1615–1619. DOI: 10.1023/A:1018924820333. PMID: 8290474.
22. Ford AC, Bernstein CN, Khan KJ, et al. 2011; Glucocorticosteroid therapy in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol. 106:590–600. DOI: 10.1038/ajg.2011.70. PMID: 21407179.
Article
Full Text Links
  • KJG
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr